Fulvestrant (Faslodex) shows promise as first-line treatment for advanced breast cancer

Breast cancer, now a cancer that can be treated completely when diagnosed early, has many treatment options: surgery, chemotherapy, radiotherapy, hormonal therapy and targeted therapy. Which option or combination is selected depends on the tumor's biology, type, size, extent of spread and the patient's overall performance.
Breast cancer is examined in four main types. The most common group is hormone receptor-positive , meaning those benefiting from hormonal therapy, which constitute more than %50 of all breast cancers. Another patient-related factor determining the basic strategy is menopausal status. Postmenopausal patients with hormone-sensitive metastatic breast cancer respond to hormonal therapy almost more than to chemotherapy. The most appropriate approach is to start hormonal therapy before chemotherapy. The study whose results we share today may change our approach to hormone-sensitive breast cancer that has spread throughout the body (metastatic). The general approach in metastatic breast cancer is to use a regimen as long as it works, continuing while a response is obtained and no intolerable side effects occur. Physicians also want to choose the most beneficial treatment with the fewest side effects.
One respected oncology journal, the Journal of Clinical Oncology, published this study in its September 2015 issue. In postmenopausal women with hormone receptor-positive breast cancer, first-line use (as the initial treatment option) of Fulvestrant, a hormonal therapy previously preferred in the second line, provided surprisingly substantial benefit.
- The study enrolled 205 postmenopausal women with breast cancer. They had hormone (estrogen) receptor-positive disease and had not previously received treatment for advanced disease. Some of these patients with locally advanced or advanced disease received Fulvestrant (Faslodex), while others received Anastrozole (Arimidex), a standard first-line hormonal option.
- When the results were analyzed, the positive response (clinical benefit) rate was % 72 with Fulvestrant and %67 with Anastrozole. Median time to disease worsening was 23 months with Fulvestrant and 13 months with Arimidex. Patients receiving Fulvestrant therefore benefited from treatment for nearly twice as long, and this positive difference also significantly prolonged survival.
Currently approved only for second-line use in our country, Fulvestrant (Faslodex), we believe, will probably push toward first-line use through this study. The success of such treatments, which prolong life without serious side effects and keep patients away from chemotherapy as much as possible, makes us oncologists happy and takes our hope another step forward each day.
Sources
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
J Clin Oncol. 2015 Sep 14. pii: JCO.2015.61.5831.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.